The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
jetcityimage / iStock Editorial via Getty Images Lilly posted 53.9% revenue growth and 480% net income growth driven…
Johnson & Johnson, U.S. agree on drug discounts, new plants
Key Terms
tariffs
regulatory
Tariffs are taxes imposed by a government on goods…
Johnson & Johnson MedTech submits Ottava surgical robot to FDA
Johnson & Johnson MedTech (NYSE: JNJ) + announced today that it submitted its Ottava surgical robotic system to…
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
Chicago, IL – January 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog.…
Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever
Bristol Myers Squibb is a pharmaceutical giant with a solid dividend history. Medtronic is a high-yield medical device…
Johnson & Johnson halts mid-stage trial of experimental eczema drug
Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg |…
Here’s Why Johnson & Johnson (JNJ) Surged in Q3
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” third-quarter 2025 investor letter. A copy of…
Stock market today: Live updates
Traders work on the floor of the New York Stock Exchange (NYSE) at the opening bell in New…
5 Dividend Powerhouses That Belong in Every Retirement Portfolio Right Now
24/7 Wall St Verizon offers the highest yield at 6.59% with a 0.32 beta and 19 consecutive years…
Johnson & Johnson (JNJ) Announces Updated Results From the Phase 3 CARTITUDE-4 Study
Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in. Johnson & Johnson (NYSE:JNJ) announced…
1 Major Factor Behind the Healthcare Sector’s Recent Surge
Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other…
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following…